D.E. Shaw & Co
PGEN icon

D.E. Shaw & Co’s Precigen PGEN Stock Holding History

D.E. Shaw & Co’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-424,900
Closed -$476K – 4621
2024
Q4 		$476K Sell
424,900
-792,731
-65% -$676K ﹤0.01% 3650
2024
Q3 		$1.15M Sell
1,217,631
-511,311
-30% -$645K ﹤0.01% 3174
2024
Q2 		$2.73M Sell
1,728,942
-55,944
-3% -$81.2K ﹤0.01% 2353
2024
Q1 		$2.59M Buy
1,784,886
+775,439
+77% +$1.11M ﹤0.01% 2426
2023
Q4 		$1.35M Buy
1,009,447
+355,755
+54% +$418K ﹤0.01% 2933
2023
Q3 		$928K Buy
653,692
+50,947
+8% +$72.2K ﹤0.01% 3107
2023
Q2 		$693K Sell
602,745
-156,739
-21% -$185K ﹤0.01% 3271
2023
Q1 		$805K Buy
759,484
+13,000
+2% +$18.7K ﹤0.01% 3303
2022
Q4 		$1.13M Buy
746,484
+99,602
+15% +$171K ﹤0.01% 3356
2022
Q3 		$1.37M Sell
646,882
-149,964
-19% -$316K ﹤0.01% 3336
2022
Q2 		$1.07M Sell
796,846
-71,710
-8% -$106K ﹤0.01% 3591
2022
Q1 		$1.83M Buy
868,556
+788,222
+981% +$1.92M ﹤0.01% 3389
2021
Q4 		$298K Buy
80,334
+10,714
+15% +$46.1K ﹤0.01% 4681
2021
Q3 		$347K Sell
69,620
-172,887
-71% -$995K ﹤0.01% 4278
2021
Q2 		$1.58M Sell
242,507
-504,305
-68% -$3.52M ﹤0.01% 3164
2021
Q1 		$5.15M Buy
746,812
+53,022
+8% +$448K 0.01% 1823
2020
Q4 		$7.08M Buy
693,790
+401,134
+137% +$2.6M 0.01% 1605
2020
Q3 		$1.02M Sell
292,656
-51,178
-15% -$243K ﹤0.01% 2837
2020
Q2 		$1.72M Buy
343,834
+217,007
+171% +$738K ﹤0.01% 2530
2020
Q1 		$431K Sell
126,827
-363,449
-74% -$1.57M ﹤0.01% 3282
2019
Q4 		$2.69M Buy
490,276
+429,039
+701% +$2.41M ﹤0.01% 2232
2019
Q3 		$351K Buy
61,237
+44,294
+261% +$301K ﹤0.01% 3375
2019
Q2 		$130K Buy
+16,943
New +$91.2K ﹤0.01% 3521
2019
Q1 		– Sell
-61,868
Closed -$405K – 3844
2018
Q4 		$405K Sell
61,868
-190,037
-75% -$2.13M ﹤0.01% 3207
2018
Q3 		$4.34M Buy
251,905
+215,863
+599% +$3.21M 0.01% 1669
2018
Q2 		$503K Sell
36,042
-67,156
-65% -$1.13M ﹤0.01% 3114
2018
Q1 		$1.58M Sell
103,198
-303,159
-75% -$4.33M ﹤0.01% 2198
2017
Q4 		$4.68M Sell
406,357
-105,387
-21% -$1.57M 0.01% 1529
2017
Q3 		$9.73M Buy
511,744
+52,890
+12% +$1.09M 0.01% 961
2017
Q2 		$11.1M Sell
458,854
-27,131
-6% -$595K 0.02% 855
2017
Q1 		$9.63M Buy
485,985
+68,535
+16% +$1.53M 0.02% 906
2016
Q4 		$10.1M Buy
417,450
+320,440
+330% +$8.92M 0.02% 937
2016
Q3 		$2.69M Buy
+97,010
New +$2.57M ﹤0.01% 1694
2016
Q1 		– Sell
-17,452
Closed -$521K – 3692
2015
Q4 		$521K Buy
17,452
+1,665
+11% +$56.1K ﹤0.01% 3071
2015
Q3 		$498K Sell
15,787
-27,068
-63% -$1.32M ﹤0.01% 3060
2015
Q2 		$2.07M Buy
42,855
+18,277
+74% +$770K ﹤0.01% 2189
2015
Q1 		$1.07M Sell
24,578
-4,477
-15% -$161K ﹤0.01% 2515
2014
Q4 		$764K Buy
+29,055
New +$637K ﹤0.01% 3025
2014
Q3 		– Sell
-9,518
Closed -$229K – 4317
2014
Q2 		$229K Buy
+9,518
New +$193K ﹤0.01% 3935
2014
Q1 		– Sell
-14,256
Closed -$324K – 4531
2013
Q4 		$324K Buy
+14,256
New +$288K ﹤0.01% 4017

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

D.E. Shaw & Co's PGEN Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Precigen (PGEN) in Q1 2025, closing a stake of 424,900 shares — an estimated $476K sold.

D.E. Shaw & Co first reported a position in PGEN in Q4 2013 and held it in 40 quarters. The position peaked at $11.1M in Q2 2017. 138 funds tracked by Wall St. Rank hold PGEN as of Q1 2025.

  • D.E. Shaw & Co reported no remaining Precigen position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 424,900 Precigen shares in Q1 2025, an estimated $476K.
  • D.E. Shaw & Co first reported a position in Precigen in Q4 2013 and held it in 40 quarters.
  • D.E. Shaw & Co's Precigen position peaked at $11.1M in Q2 2017.
  • 138 funds tracked by Wall St. Rank held Precigen as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.